We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Diagnostic Test for Lung Cancer Is Highly Accurate

By Biotechdaily staff writers
Posted on 09 Oct 2007
A study found that a molecular diagnostic test for lung cancer demonstrated high levels of accuracy.

A standardized reverse transcription polymerase chain reaction (StaRT-PCR) platform technology was used for measuring messenger RNA (mRNA) transcripts levels of 15 genes that could serve to predict lung cancer. More...
The test for these genes, in normal cells sampled via bronchoscopy, identified those individuals genetically at risk for lung cancer. In a study of 49 subjects, the test was able to correctly identify the individuals with cancer 96% of the time.

James C. Willey, M.D., founder and chief science and medical consultant to the company Gene Express (Toledo, OH, USA), and colleagues from the University of Toledo (OH, USA) measured transcript abundance (TA) of 15 genes that encode protective antioxidant and DNA repair proteins in lung airway cells taken from 25 people with lung cancer and 24 people without the disease. Their previous research allowed them to determine the threshold levels of TA for each gene--the point at which the amount of mRNA transcripts would indicate a tendency toward cancer. In this study, they used the threshold levels as a basis to assign a value of one or zero to each of the targeted genes for an individual subject, with "zero” indicating normal TA.

If the sum total of a subject's target genes was greater than or equal to seven, the genes could collectively serve as a biomarker for lung cancer. The results yielded one false negative and seven false positives among the 49 individuals assessed. According to Dr. Willey, a positive result in a subject without lung cancer may not actually be a false positive, but rather could mean that the person is at an increased risk for lung cancer, which might arise later.

"Overall, the study showed a high degree of accuracy for picking out lung cancer patients,” said Dr. Willey. CEO of Gene Express, Gerald Vardzel added, "We are excited about these results, as they demonstrate the value of our platform technology in the development of molecular diagnostics and the movement towards personalized medicine.”

The study was presented at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development in September 2007, which was held in Atlanta, GA (USA).


Related Links:
Gene Express
University of Toledo

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.